In contrast to spinal muscular atrophy, UniQure Biopharma is developing AAV5-miHTT (AMT-130), and the University of Massachusetts Medical School is developing AAVrh10 miR-SOD1 injection; both are in the first phase of clinical trials, according to May’21 data. Here, SOD1 is linked to proximal spinal muscular atrophy.